Fusion to a highly charged proteasomal retargeting sequence increases soluble cytoplasmic expression and efficacy of diverse anti-synuclein intrabodies

mAbs

Volumn 4, Issue 6, 2012, Pages 686-693

  Joshi, Shubhada N ^a   Butler, David C ^b   Messer, Anne ^a,b  

^a ALBANY MEDICAL COLLEGE   (United States)

^b STATE UNIVERSITY OF NEW YORK   (United States)

Author keywords

synuclein; Intrabodies; Intrabody PEST fusions; Parkinson disease; Proteasome

Indexed keywords

10H ANTIBODY; ALPHA SYNUCLEIN ANTIBODY; ANTIBODY; D10 ANTIBODY; D5E ANTIBODY; HYBRID PROTEIN; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; UNCLASSIFIED DRUG; VH14 NANOBODY ANTIBODY;

AMINO ACID SEQUENCE; ARTICLE; PROTEIN EXPRESSION;

Α-SYNUCLEIN; INTRABODIES; INTRABODY-PEST FUSIONS; PARKINSON DISEASE; PROTEASOME;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODY AFFINITY; CELL LINE; CYTOPLASM; GENE EXPRESSION REGULATION; HUMANS; PARKINSON DISEASE; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN BINDING; PROTEIN ENGINEERING; PROTEIN SORTING SIGNALS; RATS; RECOMBINANT FUSION PROTEINS; SINGLE-CHAIN ANTIBODIES; SOLUBILITY; SYNUCLEINS;

EID: 84869817635     PISSN: 19420862     EISSN: 19420870     Source Type: Journal    
DOI: 10.4161/mabs.21696     Document Type: Article

References (29)

1. Miller TW, Messer A. Intrabody applications in neurological disorders: progress and future prospects. Mol Ther 2005; 12:394-401; PMID:15964243; http://dx.doi.org/10.1016/j.ymthe.2005.04.003
2. Messer A, Lynch SM, Butler DC. Developing intrabodies for the therapeutic suppression of neurodegenerative pathology. Expert Opin Biol Ther 2009; 9:1189-97; PMID:19653865; http://dx.doi.org/10.1517/14712590903176387
3. Huston JS, Levinson D, Mudgett-Hunter M, Tai MS, Novotný J, Margolies MN, et al. Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli. Proc Natl Acad Sci U S A 1988; 85:5879-83; PMID:3045807; http://dx.doi.org/10.1073/pnas.85.16.5879
4. Butler DC, McLear JA, Messer A. Engineered antibody therapies to counteract mutant huntingtin and related toxic intracellular proteins. Prog Neurobiol 2012; 97:190-204; PMID:22120646; http://dx.doi.org/10.1016/j. pneurobio.2011.11.004
5. Kvam E, Sierks MR, Shoemaker CB, Messer A. Physico-chemical determinants of soluble intrabody expression in mammalian cell cytoplasm. Protein Eng Des Sel 2010; 23:489-98; PMID:20378699; http://dx.doi.org/10.1093/protein/gzq022
6. Ellis RJ. Macromolecular crowding: an important but neglected aspect of the intracellular environment. Curr Opin Struct Biol 2001; 11:114-9; PMID:11179900; http://dx.doi.org/10.1016/S0959-440X(00)00172-X
7. Wörn A, Plückthun A. An intrinsically stable antibody scFv fragment can tolerate the loss of both disulfide bonds and fold correctly. FEBS Lett 1998; 427:357-61; PMID:9637257; http://dx.doi.org/10.1016/S0014-5793(98) 00463-3
8. Rechsteiner M, Rogers SW. PEST sequences and regulation by proteolysis. Trends Biochem Sci 1996; 21:267-71; PMID:8755249
9. Rogers S, Wells R, Rechsteiner M. Amino acid sequences common to rapidly degraded proteins: the PEST hypothesis. Science 1986; 234:364-8; PMID:2876518; http://dx.doi.org/10.1126/science.2876518
10. Butler DC, Messer A. Bifunctional anti-huntingtin proteasome-directed intrabodies mediate efficient degradation of mutant huntingtin exon 1 protein fragments. PLoS One 2011; 6:e29199; PMID:22216210; http://dx.doi.org/10.1371/ journal.pone.0029199
11. Emadi S, Barkhordarian H, Wang MS, Schulz P, Sierks MR. Isolation of a human single chain antibody fragment against oligomeric alpha-synuclein that inhibits aggregation and prevents alpha-synuclein-induced toxicity. J Mol Biol 2007; 368:1132-44; PMID:17391701; http://dx.doi.org/10.1016/j.jmb.2007.02.089
12. Emadi S, Kasturirangan S, Wang MS, Schulz P, Sierks MR. Detecting morphologically distinct oligomeric forms of alpha-synuclein. J Biol Chem 2009; 284:11048-58; PMID:19141614; http://dx.doi.org/10.1074/jbc.M806559200
13. Zhou C, Emadi S, Sierks MR, Messer A. A human single-chain Fv intrabody blocks aberrant cellular effects of overexpressed alpha-synuclein. Mol Ther 2004; 10:1023-31; PMID:15564134; http://dx.doi.org/10.1016/j.ymthe.2004.08.019
14. Emadi S, Liu R, Yuan B, Schulz P, McAllister C, Lyubchenko Y, et al. Inhibiting aggregation of alpha-synuclein with human single chain antibody fragments. Biochemistry 2004; 43:2871-8; PMID:15005622; http://dx.doi.org/10. 1021/bi036281f
15. Giasson BI, Murray IV, Trojanowski JQ, Lee VM. A hydrophobic stretch of 12 amino acid residues in the middle of alpha-synuclein is essential for filament assembly. J Biol Chem 2001; 276:2380-6; PMID:11060312; http://dx.doi.org/10.1074/jbc.M008919200
16. Periquet M, Fulga T, Myllykangas L, Schlossmacher MG, Feany MB. Aggregated alpha-synuclein mediates dopaminergic neurotoxicity in vivo. J Neurosci 2007; 27:3338-46; PMID:17376994; http://dx.doi.org/10.1523/JNEUROSCI. 0285-07.2007
17. Lynch SM, Zhou C, Messer A. An scFv intrabody against the nonamyloid component of alpha-synuclein reduces intracellular aggregation and toxicity. J Mol Biol 2008; 377:136-47; PMID:18237741; http://dx.doi.org/10.1016/j.jmb.2007. 11.096
18. Dudgeon K, Famm K, Christ D. Sequence determinants of protein aggregation in human VH domains. Protein Eng Des Sel 2009; 22:217-20; PMID:18957405; http://dx.doi.org/10.1093/protein/gzn059
19. Wheeler YY, Chen SY, Sane DC. Intrabody and intrakine strategies for molecular therapy. Mol Ther 2003; 8:355-66; PMID:12946308; http://dx.doi.org/10. 1016/S1525-0016(03)00183-7
20. Kuo CL, Oyler GA, Shoemaker CB. Accelerated neuronal cell recovery from Botulinum neurotoxin intoxication by targeted ubiquitination. PLoS One 2011; 6:e20352; PMID:21629663; http://dx.doi.org/10.1371/journal.pone.0020352
21. Rondon IJ, Marasco WA. Intracellular antibodies (intrabodies) for gene therapy of infectious diseases. Annu Rev Microbiol 1997; 51:257-83; PMID:9343351; http://dx.doi.org/10.1146/annurev.micro.51.1.257
22. Zhu Q, Zeng C, Huhalov A, Yao J, Turi TG, Danley D, et al. Extended half-life and elevated steady-state level of a single-chain Fv intrabody are critical for specific intracellular retargeting of its antigen, caspase-7. J Immunol Methods 1999; 231:207-22; PMID:10648939; http://dx.doi.org/10.1016/ S0022-1759(99)00158-1
23. Li X, Zhao X, Fang Y, Jiang X, Duong T, Fan C, et al. Generation of destabilized green fluorescent protein as a transcription reporter. J Biol Chem 1998; 273:34970-5; PMID:9857028; http://dx.doi.org/10.1074/jbc.273.52.34970
24. Leclerc GM, Boockfor FR, Faught WJ, Frawley LS. Development of a destabilized firefly luciferase enzyme for measurement of gene expression. Biotechniques 2000; 29:590-1, 594-6, 598 passim; PMID:10997273
25. Leclerc GM, Boockfor FR, Faught WJ, Frawley LS. Development of a destabilized firefly luciferase enzyme for measurement of gene expression. Biotechniques 2000; 29:590-1, 594-6, 598 passim; PMID:10997273
26. Sibler AP, Courtête J, Muller CD, Zeder-Lutz G, Weiss E. Extended half-life upon binding of destabilized intrabodies allows specific detection of antigen in mammalian cells. FEBS J 2005; 272:2878-91; PMID:15943819; http://dx.doi.org/10.1111/j.1742-4658.2005.04709.x
27. Lecerf JM, Shirley TL, Zhu Q, Kazantsev A, Amersdorfer P, Housman DE, et al. Human singlechain Fv intrabodies counteract in situ huntingtin aggregation in cellular models of Huntington's disease. Proc Natl Acad Sci U S A 2001; 98:4764-9; PMID:11296304; http://dx.doi.org/10.1073/pnas.071058398
28. Li X, Coffino P. Distinct domains of antizyme required for binding and proteolysis of ornithine decarboxylase. Mol Cell Biol 1994; 14:87-92; PMID:8264655
29. Zhang M, MacDonald AI, Hoyt MA, Coffino P. Proteasomes begin ornithine decarboxylase digestion at the C terminus. J Biol Chem 2004; 279:20959- 65; PMID:15016805; http://dx.doi.org/10.1074/jbc.M314043200